# CodeBreaK 200 (NCT04303780)

> Study to Compare AMG 510 "Proposed INN Sotorasib" With Docetaxel in Non Small Cell Lung Cancer (NSCLC) (CodeBreak 200).

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT04303780
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Amgen
- Conditions: KRAS p, G12c Mutated /Advanced Metastatic NSCLC
- Interventions: AMG 510; Docetaxel
- Enrollment: 345
- Primary outcome: Progression-free Survival (PFS)

## Questions raised in the commentary

_Automated, Oct 29, 2026. Not an Erudio report: no source links. Not medical advice._

The commentary discusses CodeBreaK 200’s comparison of sotorasib with docetaxel, patient-reported outcomes, and how trial design affects interpretation. Speakers raise concerns about randomization, open-label bias, blinded independent review, censoring, and the reliability of progression-free survival assessment. Crossover and post-protocol care are discussed in relation to whether overall-survival effects can be interpreted, including whether a survival decrement can be excluded. Commentary also considers the control regimen, the clinical meaning of hazard ratios, and whether the evidence supports regular FDA approval or changes practice.

## Indexed commentary on CodeBreaK 200 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 81
- Podcasts: 35
- YouTube: 28
- Bluesky threads: 2

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=codebreak-200-nct04303780

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT04303780", "email": "<work email>"}; the inbox owner confirms by the emailed link.